All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael Manns(Medizinische Hochschule Hannover), Stephanie Noviello(Novartis (United States)), Youn Jae Lee(Inje University Busan Paik Hospital), Patrick Marcellin(Inserm), Guido Gerken, Marc Bourlière(Universität Hamburg), Justin Kopit(Gdańsk Medical University), Jeong Heo(National Cancer Center), Stuart C. Gordon(United States Department of Veterans Affairs), Patricia Méndez, Gregory T. Everson(ColdQuanta, Inc., DBA Infleqtion (United States)), Misti Linaberry(Bristol-Myers Squibb (United States)), Jia‐Horng Kao(National Taiwan University Hospital), Cheng‐Yuan Peng(China Medical University), William Sievert(Monash Health), Ira M. Jacobson(Cornell University), Sophie Métivier, Fiona McPhee(Bristol-Myers Squibb (United States)), William Towner(Kaiser Permanente), Boris Yoffe(Baylor College of Medicine), Chi‐Jen Chu(Taipei Veterans General Hospital), Jean–Pierre Bronowicki(Inserm), S. Pol(Hôpital Cochin), Dominique Thabut(Inserm), Ting‐Tsung Chang(National Cheng Kung University Hospital), Eric Hughes(The University of Texas at San Antonio Health Science Center)
Cited by 343
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
|New England Journal of Medicine|2004|1.1k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k